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For many, the final terminal event in life is cessation of the heart beat. In turn, this is generally because this organ has been deprived of oxygen
and glucose as the blood can no longer deliver these requirements to the myocardium. The principal reason for this is blockage of one or more
coronary arteries or arterioles by platelet rich thrombus. A similar process exists for the pathophysiology of stroke—a disabilitating and often fatal
event caused by occlusion or rupture of arteries in, or feeding, the brain. These scenarios are best developed in cardiovascular disease, but apply to
almost all human disease. Therefore, the ultimate culprit for these major life events is the overactive platelet—too ready to form an inappropriate
thrombus. Thus, one way forward in postponing an occlusive thrombotic event is to minimise platelet activation, new tools and treatments for
which are eagerly sought.
© 2007 Elsevier B.V. All rights reserved.Keywords: Platelets; Thrombosis; P selectinHave platelets caused the greater proportion of human
mortality and morbidity?What is their role in the cardiovascular,
connective tissue and neoplastic disease that will strike the
majority of the Western world and an increasing proportion of
those in the developing world? Historically, pathophysiological
aspects of platelet biology have focussed on their relatively
passive and reactive roles in minimising blood loss after injury
(desirable thrombosis), in contributing to the final stages of
cardiovascular disease and its risk factors (largely in the in-
appropriate formation of life-threatening undesirable thrombo-
sis), and on attempts in the out-patient and General Practice
clinic, the cardiac catheter suite, and on the ward to reduce the
risk of these thromboses with anti-coagulant and anti-platelet
agents. Indeed, some data (e.g. adhesion of platelets to the
endothelium prior to the development of manifest atherosclero-
tic lesions) have prompted the placement of platelets much
closer to the centre of cardiovascular disease, hypothesising that
platelets actually trigger atherosclerosis [1–3]. But perhaps the
most compelling evidence of the importance of this cell are the
beneficial results of trials of anti-platelet drugs, of which the
principles are aspirin and clopidogrel [4–6].⁎ Tel./fax: +44 121 507 5076.
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doi:10.1016/j.bbadis.2007.03.001Our colleagues in oncology have long had an interest in
coagulation and the platelet, and thus, in thrombosis. For
example, patients with cancer are at risk of venous thromboem-
bolism, have raised plasma fibrinogen, von Willebrand factor
and fibrin degradation products, and thrombocytosis can be used
as an independent prognostic indicator [7]. Indeed, several
commentators have mused that hypercoagulability preceeds
cancer [8]. However, a more cancer-specific role for the platelet
in this type of disease has been proposed by Pinedo et al. [9],
who suggest that differences in the release of pro-angiogenic
(e.g. platelet derived growth factor, angiopoietin) and anti-
angiogenic (e.g. platelet factor 4, thrombospondin) factors by
this cell modifies the angiogenic balance of a tumour and its
ability to metastasise. Data supporting this hypothesis has been
produced by several groups, who have showed not only that
platelets carry the pro-angiogenic vascular endothelial growth
factor but also release it upon activation by thrombin [10,11]).
Similarly, Caine et al. have reported that the inflammatory
cytokine IL-6 will cause the dose-dependent release of VEGF
from normal platelets in vitro [12], whilst Rosselli et al. [13]
have demonstrated a strong correlation between VEGF and
platelet counts as well as with a plasma marker of platelet
activation (soluble P selectin) in both squamous and adenoma
variants of non-small cell lung cancer, suggesting that the
Table 1
The platelet in human disease
Cardiovascular disease
▪ Platelets are present in atheroma
▪ Rupture of the atheroma, alongside circulating thrombus, are responsible for
acute coronary syndromes such as myocardial infarction and angina
▪ Platelets contribute to deep vein thrombosis and pulmonary embolism
▪ Anti-platelet drugs effective in postponing major clinical events such as
myocardial infarction and stroke
Cancer
▪ Platelets carry vascular endothelial growth factor
(although it is unclear whether or not this is clinically relevant)
▪ Patients with existing cancer are at risk of venous thrombosis
▪ Patients with an unexplained venous thrombosis are often found later to have
an asymptomatic cancer
Connective tissue disease
▪ Raised platelet count often present in rheumatoid arthritis
▪ Increased numbers of pro-thrombotic platelet microparticles in systemic lupus
erythematosus
▪ Connective tissue disease inevitable progresses to the cardiovascular system
and thus major event such as venous and arterial thrombosis
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therefore possible (at least in theory) that platelets may be
important in angiogenesis and in wound healing.
Thrombocytosis and abnormalities in platelet function have
long been a recognised feature of connective tissue diseases
such as rheumatoid arthritis and systemic lupus erythematosus
and, of course, aspirin is for many the first line of treatment
[14–16]. Increased numbers of platelet microparticles (frag-
ments of cytoplasm) with pro-thrombotic potential [17] may
contribute to the increased risk of disease in this group.
However, the latter stages of the disease certainly involve
thrombosis, such that the terminal events are cardiovascular
(e.g. pulmonary embolism, myocardial infarction and stroke).
Accordingly, rheumatoid disease may indeed be seen as an
additional risk factor for cardiovascular disease in the same light
as is diabetes and hypertension. Finally, inflammation (in the
absence of a connective tissue component) has been strongly
promoted as a player in the complex pathophysiology of
atherosclerosis, and this extends to the platelet [12,18,19].
Thus the platelet and coagulopathy are target for each of the
major disease processes that afflict our species (Table 1), but
what tools do we have to study the pathophysiology of this cell?
A major problem with the study of the isolated platelet (when
obtained from venous blood for studies such as aggregometry or
adhesion) is that their fragile nature leads to the strong
likelihood of an ex-vivo (and therefore artifactual) effect.
Complex analyses such as are offered by flow cytometry may
also provide useful, although possibly also artefactual, data,
although this approach, by its nature, does not lend itself to
high-throughput research. However, flow cytometry, directed
towards surface molecules such as CD63 and gpIIb/IIIa (which
binds fibrinogen), can be performed on whole blood, thus
avoiding the preparation artefact of a purified population of
platelets. A third opportunity to study this cell is by its secreted
products. When activated (by, for example, thrombin or aden-osine diphosphate), platelets release the contents of their alpha
granules, such as beta thromboglobulin and platelet factor four,
which can be measured in plasma by enzyme linked
immunosorbent assay (ELISA). A parallel event in this de-
granulation is the appearance, at the cell surface, of the adhesion
molecule CD62P, also known as P selectin, which can be
detected by flow cytometry. However, using ELISA, a form of
P selectin can also be found in the plasma (i.e. soluble
P-selectin), and this product is becoming recognised as a
valuable tool for assessing platelet activation in vivo and in
vitro [20]. This molecule may also, under certain circumstances,
be found on the surface of the endothelial cell, leading to
confusion in some minds regarding the origin of the plasma
form. However, is now clear that the platelet is the major source
of soluble P selectin ([20], and references therein).
These tools therefore, provide the opportunity to study the
pathophysiology of thrombosis. However, some crucial ques-
tions can only be answered in animal model (presuming, of
course, that the biology of the particular species reflects that of
our species, which is frequently not the case [21]), and in this
respect the P selectin knock-out mouse has proved fascinating
[22]. Nevertheless, some tools cannot easily be carried across
species, and monoclonal antibodies (mAbs) are good example
of this problem as those directed towards humans invariably fail
to react to the same molecules of common laboratory animals,
frustrating the clinical scientists. But one source of frustration
has recently been relieved by the production of a series of
mAb's specific for rat P selectin. In the current issue of this
Journal, Hirose et al. report the development and application of
such reagents from hybridoma cell lines using rat platelets
stimulated with thrombin as immunogens [23]. They use it to
demonstrate that soluble P selectin could serve as a marker of
lung inflammation and thus, by extrapolation, a new tool for
studying thrombosis in this and other settings. An additional
point of interest in the large variation in soluble P selectin
between different strains of rat—a phenomenon not (yet)
reported in our own species. These anti-rat P-selectin antibodies
therefore may well open up a new field of potential research in
this most common pathophysiology of human diseases.
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